Karuna Therapeutics Inc. (KRTX) Prices 2.6M Share Offering at $96/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
After-Hours Movers 11/20: (XXII) (NUAN) (TIF) Higher; (OPTN) (LZB) (CUB) Lower (more...)
November 20, 2019 6:00 PM ESTAfter-Hours Movers
Optinose (NASDAQ: OPTN) 10.2% LOWER; announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an underwritten public offering.
La-Z-Boy (NYSE: LZB) 8.6% LOWER; reported Q2 EPS of $0.52, $0.02 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $447.2 million versus the consensus estimate of $454.39 million.
22nd Century Group (NYSE: XXII) 7.8% HIGHER; rebounds slightly after falling 43%... More
Karuna Therapeutics Inc. (KRTX) PT Raised to $134 at Wedbush
November 20, 2019 4:18 PM ESTWedbush analyst Liana Moussatos raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $134.00 (from $38.00) while maintaining a Outperform rating.
... MoreKaruna Therapeutics Inc. (KRTX) Climbs 30%
November 19, 2019 10:36 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Climbs 30%
... MoreKaruna Therapeutics Inc. (KRTX) Halted on LUDP
November 19, 2019 10:18 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP
... MorePre-Open 11/19: (MYOV) (MDCO) (VKTX) Higher (I) (KSS) (HD) Lower (more...)
November 19, 2019 9:13 AM ESTPre-Open Movers
Myovant Sciences (NYSE: MYOV) 65.8% HIGHER; announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. These results support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020 and future regulatory submissions in Europe and Japan.
Medicines Co. (NASDAQ:... More
